Biotechs face brutal pipeline decisions as industry waits for M&A 'buffet' GSK turns down one solid tumor collaboration, but Ideaya thinks it’s for the best Pyxis puts 2 drugs on backburner and a 3rd on the scrapheap to rally resources behind lead cancer programs Atai says goodbye to pipeline prospects, slimming down and taking on debt to extend cash runway Clene claims MS drug win, but COVID disruption masks some tricky data Checkpoint calls it quits on cancer drug trial, citing enrollment problems stemming from war in Ukraine Time may be running out for anti-aging biotech AgeX as funds dry up Democrats' drug pricing reforms may not be so bad for pharma, analysts say Boston Scientific bulks up blood-blocking portfolio with Obsidio acquisition With Pfizer, AZ and Merck leading the way, Big Pharma weathered the economic storm in Q2 Health tech Q2 earnings update—GoodRx resolves grocer spat; Progyny sees strong demand for fertility benefits Illumina sets aside $453M to prep for potential EU fines over Grail acquisition Featured Story | By Annalee Armstrong We’re seeing a seemingly unprecedented reckoning from biotech C-suites, where executives are making tough calls about continuing to keep the lights on or cutting once-promising candidates. read more |
| |
|---|
|
Top Stories By James Waldron GSK has passed on the chance to go all-in on one of its cancer collaborations with Ideaya Biosciences, but the precision medicine company feels fine about the decision. read more By Nick Paul Taylor Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs to clinical data drops. read more By Nick Paul Taylor Atai Life Sciences is among the better-capitalized biotechs, ending June with $312 million left over from its private rounds and IPO. But the mental health player has still joined the growing list of companies that are trimming their pipelines and taking on debt to keep priority programs moving forward read more By James Waldron Clene Nanomedicine has chalked up a win for its gold nanocrystal suspension to treat multiple sclerosis—although it looks like the COVID-19 pandemic may have lent a helping hand. read more By Max Bayer Checkpoint is calling it quits on a phase 3 combo trial of its lead cancer med because of the ongoing war in Ukraine. The company had the majority of its trial sites in Russia and says it's dealt with a "substantially longer" enrollment period than expected. read more By Gabrielle Masson AgeX Therapeutics, a preclinical biotech looking to turn back the clock on aging, may have to wind down, announcing “substantial doubt” about its ability to continue as money runs dry and debts mount. read more By Fraiser Kansteiner After clearing the Senate early last week, the Democrats’ Inflation Reduction Act bill has made its way through the U.S. House of Representatives, paving the way for Medicare to bargain for drug prices, cap out-of-pocket costs for seniors and more. Despite the fierce resistance from the drug industry, analysts say the bill won't be so bad for biopharma players. read more By Andrea Park After a whirlwind 2021 that saw Boston Scientific gobbling up a handful of smaller companies left and right, the medtech giant’s M&A appetite seems to have slowed. read more By Kevin Dunleavy Despite a bevy of economic challenges in the second quarter, the biopharmaceutical industry got through the period with solid sales as 15 of the top 24 companies saw a revenue increase over the second quarter of 2021. Pfizer, AstraZeneca and Merck were the top gainers while Regeneron and BioNTech took the largest hits. read more By Heather Landi Digital healthcare platform GoodRx had good news to share during its second-quarter earnings call as it settled a costly spat with a grocery chain's drug store and posted financial results that beat Wall Street forecasts. read more By Conor Hale The rainy day money for potential legal troubles dragged Illumina's quarterly income into the red, while sales slumped due to global macroeconomic challenges and the company cut back its financial outlook for the year. read more | | New Product Planning Summit September 19-20, 2022 | Boston, MA Join us for the ONLY conference for defining how the new product planning role and related functions make informed, value-based, data-driven decisions about products in the pipeline. Register now! |
|---|
Resources Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 